MedTrace Logo

Effect of Intranasal Anti-IgE Antibodies on IgE Production

NCT03019237 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-01-12

No results posted yet for this study

Summary

In this study, participants will receive either intranasal anti-IgE-antibodies (n=5) or intranasal allergen (n=5) or intranasal placebo (n=5). Blood samples will be obtained before nasal administration of study drugs and 3, 5 and 8 weeks thereafter. In the serum samples, specific and total IgE levels will be assessed.

Conditions

  • Allergy

Interventions

DRUG

anti-IgE

intranasal anti-IgE

OTHER

intranasal allergen

intranasal allergen

OTHER

intranasal saline

intranasal placebo

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Verena Niederberger, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03019237 on ClinicalTrials.gov